Xultophy Insulin Degludec and Liraglutide Injection

1. Indications and Usage
This combination is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not indicated for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.
2. Dosage and Administration
Recommended Dosage: The recommended starting dosage is 16 units once daily, containing 100 units/mL of insulin degludec and 1.4 mg/mL of liraglutide.
Administration: The injection should be administered subcutaneously once daily at approximately the same time each day, preferably at the same time as a meal. The injection site should be varied within the intended injection area (e.g., abdomen or thigh).
Dose Adjustments: The dosage may be increased in increments of 2 units every week as needed to achieve glycemic control, up to a maximum recommended dosage of 26 units once daily.
3. Mechanism of Action
Insulin Degludec: A long-acting insulin analog that forms multi-hexamers upon subcutaneous injection, creating a soluble depots that gradually dissociate and release insulin into the bloodstream. This results in a duration of action of more than 42 hours and a very flat pharmacodynamic profile.
Liraglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying, thereby reducing postprandial glucose excursions.
4. Safety and Warnings
Black Box Warnings:
Thyroid C-cell Tumors: Liraglutide causes thyroid C-cell tumors in rodents. It is unknown whether human use carries the same risk. This combination is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis: Acute pancreatitis, including fatal and non-fatal cases, has been reported with GLP-1 receptor agonists.
Hypoglycemia: The risk of hypoglycemia increases when this combination is used with sulfonylureas or insulin secretagogues.
Renal Impairment: Acute renal failure and worsening of chronic renal failure have been reported, often associated with nausea, vomiting, or diarrhea.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: The most common adverse reactions include hypoglycemia, nausea, diarrhea, vomiting, and injection site reactions. Nausea is generally transient and decreases with time.
Clinical Research: Clinical trials have demonstrated that this combination significantly reduces HbA1c and body weight compared to insulin degludec alone or liraglutide alone, with a low risk of hypoglycemia.
6. Drug Interactions
Oral Medications: Co-administration with oral medications may affect their absorption due to the delayed gastric emptying caused by liraglutide. Monitoring of plasma concentrations is recommended for narrow therapeutic index drugs.
SGLT2 Inhibitors: Concomitant use may increase the risk of hypoglycemia and dehydration.
CYP2C8 Inhibitors/Inducers: May affect the pharmacokinetics of insulin degludec, though clinical significance is low.
7. Pharmaceutical Information
Composition: Each mL contains 100 units of insulin degludec and 1.4 mg of liraglutide.
Appearance: The solution is a clear, colorless liquid.
Storage: Store in a refrigerator between 2°C and 8°C. Do not freeze. Once in use, it can be stored at room temperature below 30°C for up to 50 days.